- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Acquires Progynova, Cyclo-Progynova Brands from Mercury Pharma

Hyderabad: Dr. Reddy's Laboratories Ltd. has announced the acquisition of the trademarks for specialty brands Progynova and Cyclo-Progynova, along with related assets, for the Indian market from Mercury Pharma Group Limited, a UK-headquartered specialty pharmaceutical company.
Progynova® (estradiol valerate) is an oral hormone replacement therapy (HRT) indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova® (estradiol valerate and norgestrel) is a combined HRT therapy indicated for estrogen deficiency symptoms, providing both estrogen and progestogen components.
According to IQVIA MAT December 2025 data, Progynova® recorded sales of approximately ₹100 crore in India. The brand is ranked number one in the estradiol-represented pharmaceutical market (RPM) and enjoys strong physician recall and equity.
The acquisition marks Dr. Reddy’s strategic entry into the hormone replacement therapy segment and strengthens its gynaecology portfolio in India.
Commenting on the development, M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said, “The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India. With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact. Furthermore, this acquisition brings a first-in-class treatment closer to patients, underscoring our commitment to innovation and patient care at the centre of everything we do.”
Dr. Reddy’s Laboratories Ltd. is a Hyderabad-based global pharmaceutical company engaged in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. The company operates across major markets including the United States, India, Russia & CIS countries, China, Brazil, and Europe.
Also Read: Dr Reddy's Foils Email Spoofing Scam, Rs 2.16 Cr Recovered by Bengaluru Police
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

